Our News

Our News

Our News

Press Releases

Recent Media Coverage

May 12, 2022

Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors

April 4, 2022

Paracrine Announces Publication of STAR Trial, Including Improvement in Hand Function and Quality of Life in Patients with Diffuse Cutaneous Scleroderma

February 2, 2022

Paracrine to Present at Landmark's Health Innovations Forum 2022

January 25, 2022

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients with Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

January 4, 2022

Paracrine to Present at Biotech Showcase 2022

November 17, 2022

Paracrine Receives Full FDA Approval of Investigational Device Exemption (IDE) to Launch a U.S. Pivotal Trial in Patients with Diabetic Foot Ulcers

February 14, 2022

Regenerative Medicine Enabled By Point of Care Device

February 10, 2022

On Point: Paracrine's Cell Therapy Uses Adipose-Derived Regenerative Cells for Autologous Reimplantation

February 7, 2022

Escaping the "Valley of Death:" The Funding Process for Biotech Companies

January 27, 2022

FDA Clears Phase 3 Cell Therapy Trial for Diffuse SCL Hand Dysfunction

October 14, 2021

citybiz Interview: Christopher Calhoun, Founder & CEO of Paracrine Cell Therapy

October 6, 2021

Paracrine Aims to Use Its Autologous Cell Therapy Platform to Treat a Variety of Unmet Needs

Press Releases

May 12, 2022

Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors

April 4, 2022

Paracrine Announces Publication of STAR Trial, Including Improvement in Hand Function and Quality of Life in Patients with Diffuse Cutaneous Scleroderma

February 2, 2022

Paracrine to Present at Landmark's Health Innovations Forum 2022

January 25, 2022

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients with Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

January 4, 2022

Paracrine to Present at Biotech Showcase 2022

November 17, 2022

Paracrine Receives Full FDA Approval of Investigational Device Exemption (IDE) to Launch a U.S. Pivotal Trial in Patients with Diabetic Foot Ulcers

Recent Media Coverage

February 14, 2022

Regenerative Medicine Enabled By Point of Care Device

February 10, 2022

On Point: Paracrine's Cell Therapy Uses Adipose-Derived Regenerative Cells for Autologous Reimplantation

February 7, 2022

Escaping the "Valley of Death:" The Funding Process for Biotech Companies

January 27, 2022

FDA Clears Phase 3 Cell Therapy Trial for Diffuse SCL Hand Dysfunction

October 14, 2021

citybiz Interview: Christopher Calhoun, Founder & CEO of Paracrine Cell Therapy

October 6, 2021

Paracrine Aims to Use Its Autologous Cell Therapy Platform to Treat a Variety of Unmet Needs

Press Releases

May 12, 2022

Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors

April 4, 2022

Paracrine Announces Publication of STAR Trial, Including Improvement in Hand Function and Quality of Life in Patients with Diffuse Cutaneous Scleroderma

February 2, 2022

Paracrine to Present at Landmark's Health Innovations Forum 2022

January 25, 2022

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients with Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

January 4, 2022

Paracrine to Present at Biotech Showcase 2022

November 17, 2022

Paracrine Receives Full FDA Approval of Investigational Device Exemption (IDE) to Launch a U.S. Pivotal Trial in Patients with Diabetic Foot Ulcers

Recent Media Coverage

February 14, 2022

Regenerative Medicine Enabled By Point of Care Device

February 10, 2022

On Point: Paracrine's Cell Therapy Uses Adipose-Derived Regenerative Cells for Autologous Reimplantation

February 7, 2022

Escaping the "Valley of Death:" The Funding Process for Biotech Companies

January 27, 2022

FDA Clears Phase 3 Cell Therapy Trial for Diffuse SCL Hand Dysfunction

October 14, 2021

citybiz Interview: Christopher Calhoun, Founder & CEO of Paracrine Cell Therapy

October 6, 2021

Paracrine Aims to Use Its Autologous Cell Therapy Platform to Treat a Variety of Unmet Needs